Jinyu Bio-technology Co., Ltd. (SHA:600201)

Market Cap	9.33B
Revenue (ttm)	1.26B
Net Income (ttm)	79.88M
Shares Out	1.11B
EPS (ttm)	0.07
PE Ratio	115.85
Forward PE	45.62
Dividend	0.03 (0.35%)
Ex-Dividend Date	Jun 26, 2025

Volume	24,740,179
Average Volume	44,051,330
Open	8.62
Previous Close	8.63
Day's Range	8.43 - 8.68
52-Week Range	5.62 - 9.55
Beta	0.69
RSI	47.66
Earnings Date	Aug 30, 2025

About Jinyu Bio-technology

Jinyu Bio-technology Co., Ltd. develops and evaluates vaccines and reagents for animal diseases. It offers vaccines for pigs to treat swine influenza, g E gene deletion, classical swine fever, porcine parvovirus and circovirus, foot-and-mouth disease, porcine reproductive and respiratory syndrome, pseudorabies, swine erysipelas, porcine pasteurella multocida triple foot-and-mouth disease type 0, swine erysipelas, porcine pasteurella multocida, porcine paratyphoid porcine circovirus, and porcine escherichia coli; ruminants vaccines for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,740
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600201

Financial Performance

In 2024, Jinyu Bio-technology's revenue was 1.26 billion, a decrease of -21.45% compared to the previous year's 1.60 billion. Earnings were 108.99 million, a decrease of -61.57%.